Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Global Market Report 2026

Description

SPECT or PET radiopharmaceuticals are radioactive substances administered to patients that emit detectable signals, enabling imaging of physiological functions and organ activity through SPECT or PET scanning systems. These compounds release signals captured by scanners, allowing detailed evaluation of biological processes for diagnostic purposes.

The primary types of radiopharmaceuticals of single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical include single photon emission computed tomography and positron emission tomography. Single photon emission computed tomography refers to imaging agents that emit gamma rays used for diagnostic imaging of organ function and structure. These radiopharmaceuticals utilize radioisotope types such as technetium-99m, fluorine-18, iodine-123, and gallium-68, and are administered through injectable, inhalation, and oral routes. The various applications involved are oncology, cardiology, neurology, and other application areas, and they are used by several end users such as hospitals, diagnostic imaging centers, research institutions, and other end users.

Tariffs are affecting the SPECT and PET radiopharmaceuticals market by increasing the cost of radioisotopes, specialized production equipment, and transportation logistics, which ultimately leads to higher overall diagnostic and treatment expenses. Segments such as positron emission tomography and technetium-99m-based radiopharmaceuticals are especially impacted due to their dependence on global supply chains and time-sensitive distribution requirements. Regions including North America and Europe are experiencing rising cost pressures, while Asia-Pacific is facing disruptions in isotope availability within the supply chain. However, tariffs are also encouraging local production of radioisotopes and stimulating investment in domestic nuclear medicine infrastructure, thereby improving long-term supply security and reducing reliance on imports.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market research report is one of a series of new reports from The Business Research Company that provides single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market statistics, including single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry global market size, regional shares, competitors with a single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market share, detailed single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market segments, market trends and opportunities, and any further data you may need to thrive in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical industry. This single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size has grown strongly in recent years. It will grow from $6.53 billion in 2025 to $7.04 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising prevalence of cancer and cardiovascular diseases, growth in nuclear medicine infrastructure, increasing demand for functional imaging techniques, advancements in radiopharmaceutical development, expansion of diagnostic imaging centers.

The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market size is expected to see strong growth in the next few years. It will grow to $9.62 billion by 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized diagnostic solutions, growth in theranostics applications, rising investment in nuclear medicine research, advancements in radioisotope production technologies, expanding use of pet imaging in clinical practice. Major trends in the forecast period include increasing adoption of targeted radiopharmaceuticals for disease-specific imaging, growing demand for hybrid imaging techniques combining spect and pet modalities, rising use of short half-life isotopes for improved safety and imaging precision, expansion of radiopharmaceutical applications in oncology and neurology, increasing focus on early disease detection and functional imaging.

The increasing prevalence of cancer is anticipated to drive the expansion of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market going forward. Cancer refers to a group of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body, which can develop into tumors and disrupt normal physiological functions. The incidence of cancer is rising due to an aging population, as elderly individuals are more likely to accumulate genetic mutations that may lead to uncontrolled cell growth. SPECT and PET radiopharmaceuticals allow highly sensitive and accurate visualization of tumors, enabling early cancer detection, precise staging, monitoring of treatment response, and support for personalized therapy decisions. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected in 2050, representing a 77% rise compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is fueling the growth of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market.

Leading companies operating in the positron emission tomography (PET) radiopharmaceutical market are focusing on developing innovative products such as cardiac positron emission tomography (PET) tracers to improve diagnostic accuracy and accessibility in coronary artery disease imaging. Cardiac positron emission tomography (PET) tracers are radioactive compounds used in PET imaging to visualize blood flow and detect areas of reduced perfusion in the heart, helping clinicians accurately diagnose coronary artery disease and assess myocardial ischemia and infarction in a noninvasive and highly sensitive manner. For example, in September 2024, GE HealthCare, a U. S. -based medical technology and pharmaceutical diagnostics company, received U. S. Food and Drug Administration (FDA) approval for Flyrcado (flurpiridaz F 18), a cardiac PET (positron emission tomography) tracer for myocardial perfusion imaging (MPI) in patients with known or suspected coronary artery disease. Flyrcado is a ready-to-use unit dose radiotracer with a long half-life of 109 minutes, enabling high-resolution PET imaging, exercise stress testing, and rescans in the same session, improving diagnostic accuracy compared to traditional SPECT MPI agents. This approval expands access to advanced cardiac PET imaging, particularly benefiting difficult-to-image patients such as women and those with high body mass index (BMI).

In January 2026, SHINE Technologies LLC, a US-based healthcare technology and nuclear medicine production company, acquired the SPECT business of Lantheus Holdings for an undisclosed amount. With this acquisition, SHINE intends to enhance its capabilities and strengthen its market presence in nuclear medicine by taking over established SPECT diagnostic products and manufacturing operations while maintaining continuity and supporting the continued growth of the business. Lantheus Holdings Inc. is a US-based healthcare technology company that specialized in offering SPECT radiopharmaceutical diagnostic agents and related manufacturing operations used in single photon emission computed tomography imaging.

Major companies operating in the single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market are Cardinal Health Inc. , Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies Inc. , Bracco Imaging S. p. A. , Lantheus Holdings Inc. , Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc. , Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S. A. , Nordion Inc. , NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, EczacIbasI-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company

North America was the dominating region in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market consists of sales of products such as diagnostic radiotracers, therapeutic radiopharmaceuticals, and radionuclide compounds such as technetium-99m, fluorine-18, and iodine-131. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Type Of Radiopharmaceuticals: Single Photon Emission Computed Tomography; Positron Emission Tomography
2) By Radioisotope Type: Technetium-99m; Fluorine-18; Iodine-123; Gallium-68
3) By Route Of Administration: Injectable; Inhalation; Oral
4) By Application Areas: Oncology; Cardiology; Neurology; Other Application Areas
5) By End User: Hospitals; Diagnostic Imaging Centers; Research Institutions; Other End Users
Subsegments:
1) By Single Photon Emission Computed Tomography: Cardiac Imaging Agents; Bone Imaging Agents; Renal Imaging Agents; Pulmonary Imaging Agents; Thyroid Imaging Agents
2) By Positron Emission Tomography: Oncology Imaging Agents; Neurology Imaging Agents; Cardiology Imaging Agents; Infection And Inflammation Imaging Agents; Metabolic Imaging Agents
Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies Inc.; Bracco Imaging S.p.A.; Lantheus Holdings Inc.; Jubilant Pharmova Limited; Curium Pharma; Sofie Biosciences Inc.; Telix Pharmaceuticals Limited; Eckert & Ziegler SE; Advanced Accelerator Applications S.A.; Nordion Inc.; NorthStar Medical Radioisotopes LLC; ITM Isotope Technologies Munich SE; EczacIbasI-Monrol Nuclear Products; Radioisotope Centre POLATOM; IBA Radiopharma Solutions; Dongcheng; Pars Isotope Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: HS4MSECO04_G26Q2

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Sustainability, Climate Tech & Circular Economy
- 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Adoption Of Targeted Radiopharmaceuticals For Disease-Specific Imaging
- 4.2.2 Growing Demand For Hybrid Imaging Techniques Combining Spect And Pet Modalities
- 4.2.3 Rising Use Of Short Half-Life Isotopes For Improved Safety And Imaging Precision
- 4.2.4 Expansion Of Radiopharmaceutical Applications In Oncology And Neurology
- 4.2.5 Increasing Focus On Early Disease Detection And Functional Imaging

5. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Diagnostic Imaging Centers
5.3 Research Institutions
5.4 Nuclear Medicine Centers
5.5 Other End Users

6. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Size, Comparisons And Growth Rate Analysis
7.3. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Segmentation

9.1. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Single Photon Emission Computed Tomography, Positron Emission Tomography
9.2. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Radioisotope Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Technetium-99m, Fluorine-18, Iodine-123, Gallium-68
9.3. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injectable, Inhalation, Oral
9.4. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Application Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oncology, Cardiology, Neurology, Other Application Areas
9.5. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Diagnostic Imaging Centers, Research Institutions, Other End Users
9.6. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Sub-Segmentation Of Single Photon Emission Computed Tomography, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cardiac Imaging Agents, Bone Imaging Agents, Renal Imaging Agents, Pulmonary Imaging Agents, Thyroid Imaging Agents
9.7. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Sub-Segmentation Of Positron Emission Tomography, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oncology Imaging Agents, Neurology Imaging Agents, Cardiology Imaging Agents, Infection And Inflammation Imaging Agents, Metabolic Imaging Agents

10. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Regional And Country Analysis

10.1. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

11.1. Asia-Pacific Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

12.1. China Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

13.1. India Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

14.1. Japan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

15.1. Australia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

16.1. Indonesia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

17.1. South Korea Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

18.1. Taiwan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

19.1. South East Asia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

20.1. Western Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

21.1. UK Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

22.1. Germany Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

23.1. France Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

24.1. Italy Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

25.1. Spain Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

26.1. Eastern Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

27.1. Russia Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

28.1. North America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

29.1. USA Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

30.1. Canada Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

31.1. South America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

32.1. Brazil Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

33.1. Middle East Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

34.1. Africa Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market, Segmentation By Type Of Radiopharmaceuticals, Segmentation By Radioisotope Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Regulatory and Investment Landscape

36. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Competitive Landscape And Company Profiles

36.1. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Company Profiles
- 36.3.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. GE HealthCare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Bracco Imaging S.p.A. Overview, Products and Services, Strategy and Financial Analysis

37. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Other Major And Innovative Companies

Lantheus Holdings Inc., Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S.A., Nordion Inc., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, EczacIbasI-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company

38. Global Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market

41. Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market High Potential Countries, Segments and Strategies

41.1 Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market In 2030 - Countries Offering Most New Opportunities
41.2 Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market In 2030 - Segments Offering Most New Opportunities
41.3 Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer